Lamotrigine Drug Profile

Boxed warning

Stevens-Johnson syndrome/Toxic epidermal necrolysis — slow titration required

Clinical alerts

Boxed warning

1 boxed warning

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Stabilizes neuronal membranes by inhibiting voltage-sensitive sodium channels

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Mania
·Bipolar Disorder
·Bipolar II Disorder
·Bipolar Disorder Type I With Mania
·Healthy Volunteers

Monitoring

Therapeutic range: 2.5–15 mg/L

Interactions

No curated interaction pairs are recorded for Lamotrigine. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Dizziness
Headache
Diplopia
Ataxia
Nausea
Rash

Food, alcohol & herbal

Alcohol · moderate

Additive CNS depression

Pharmacokinetics

Published parameters · PMID:16412080

Half-life: 25-33 hours
Protein binding: 55%
Metabolised by: UGT1A4
Clearance: 2.5 L/h; adult epilepsy patients (monotherapy)
Volume of distribution: 95 L
Bioavailability: 98%
Renally eliminated: 10%
Model: 1-compartment

Pregnancy & lactation

Not recorded for Lamotrigine. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.